Gene or Genome – Page 4

BioCity’s SC0062 Shows Promise in Phase 2 Trial for Diabetic Kidney Disease

2 months ago talkbio0Tagged BioCity, Biopharma, Diabetic Nephropathy, EDNRA gene, ETA, Phase 2 trial, Proteinuria, SC0062

SC0062, endothelin receptor type A (ETA) antagonist, diabetic kidney disease (DKD), proteinuria reduction, phase 2 trial, BioCity Biopharma

Bluebird Bio’s Fall from Grace: Gene Therapy Pioneer Sells for $29M After $10B Valuation

2 months ago talkbio0Tagged Acquisition, Capital, Carlyle, DKK1 gene, Family Turdidae (organism), Financial Stress, gene therapy, Industry, Private Equity

Bluebird Bio, gene therapy, private equity, Carlyle, SK Capital, financial challenges, acquisition, biotech industry

EU PFAS Ban Threatens Pharmaceutical Packaging Industry: Challenges and Implications

2 months ago talkbio0Tagged chain disruption, chemical alternatives, drug safety, environmental, EU, PFAS gene, Pharmaceutical Packaging, regulatory

PFAS ban, pharmaceutical packaging, EU regulations, supply chain disruption, chemical alternatives, environmental protection, drug safety

Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns

2 months ago talkbio0Tagged Albert, Bourla, chain disruption, Drug Industry, European (ethnic group), Manufacturing, Pfizer, Tension, TNFRSF19 gene, U.S.

Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption

Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery

2 months ago talkbio0Tagged Aortic Valve Insufficiency, Drug Discovery, FOXD3 gene, Gemini of Coiled Bodies, Illumina, Incyte, Partnership

Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

2 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

FDA Approves Ono’s Romvimza for Rare Joint Tumor, Challenging Daiichi Sankyo’s Turalio

2 months ago talkbio0Tagged Approved, CSF1, CSF1 gene, Daiichi, Dosage Forms, Fibrous histiocytoma of tendon sheath, Giant Cell Tumors, Inhibitor, Joint Tumor, Romvimza, Sankyo, tenosynovial, Turalio, United States Food and Drug Administration, Vimseltinib

Romvimza, vimseltinib, tenosynovial giant cell tumor (TGCT), Ono Pharmaceutical, FDA approval, Daiichi Sankyo, Turalio, CSF1 inhibitor, rare joint tumor

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

2 months ago talkbio0Tagged Agonist, Bilirubin, Clinical Trials, Discontinuation (procedure), Hypoparathyroidism, PTH1R gene, SEP-786, Septerna

Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback

Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev

2 months ago talkbio0Tagged Antibody-Drug Conjugates, ASCO-GU, Cancer of Neck, Clinical Trials, Corbus Pharmaceuticals, CRB-701, NECTIN4 gene, Padcev, urothelial cancer

Corbus Pharmaceuticals, CRB-701, antibody-drug conjugate, Nectin-4, urothelial cancer, head and neck cancer, Padcev, clinical trial, ASCO-GU 2025

Pfizer’s Talzenna-Xtandi Combo Shows Significant Survival Benefit in Advanced Prostate Cancer

2 months ago talkbio0Tagged Clinical Trials, Gene Mutation, Inhibitor, Metastatic castration-resistant prostate cancer, Overall Survival, PARP1 gene, recombinational repair, TALAPRO-2, Talzenna, Xtandi

Talzenna, Xtandi, metastatic castration-resistant prostate cancer (mCRPC), overall survival, TALAPRO-2 trial, PARP inhibitor, homologous recombination repair (HRR) gene mutations